Health
Moderna launches COVID-19 vaccine booster study to address new variants – PMLiVE
First participants receive company’s modified vaccine candidates
Moderna has begun giving booster doses of its COVID-19 vaccine to trial participants as part of an amendment to a phase 2 clinical study.
The phase 2 trial amendment has enrolled 60 participants who have already received Moderna’s original mRNA-1273 vaccine. They will receive a single booster dose of a modified candidate addressing the B.1.351 variant or a multivalent booster candidate.
The variant-specific booster candidate – mRNA-1273.351 – encodes for the spike protein of the SARS-CoV-2 variant…
-
Noosa News15 hours agoMega-team of heavy horses sets world record at Good Old Days Festival
-
General19 hours agoEnglish springer spaniels Kelly and Milo helping fight dieback in Western Australia
-
General8 hours agoHow the internet reacted to Brisbane Broncos winning the NRL grand final
-
General18 hours agoHomicide Squad investigating ‘suspicious’ death of 84yo woman in Sydney suburb of Melonba